Ps1396 Results of Phase I/Ii Study of Nivolumab With Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients With Suboptimal Response to Primary Induction Therapy

Pirogova, Olga V.; Darskaya, Elena I.; Porunova, VV; Kudyasheva, Olga; Бабенко, Е В; Mikhailova, N.; Afanasyev, B.

doi:10.1097/01.hs9.0000563860.35670.9c

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several clinical trials have investigated the clinical benefits of checkpoint inhibitors a consolidation after stem cell transplantation in MM. Interim data of a phase I/II study of nivolumab with autologous-SCT in patients with suboptimal response to primary induction, described a 56% of improved response and an acceptable toxicity (48). In a phase 2 study, pembrolizumab in monotherapy was administered in patients who did not achieve a complete response to induction therapy.…”

Section: Discussionmentioning

confidence: 99%

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

et al. 2023

View full text Add to dashboard Cite

Immune dysfunction in patients with multiple myeloma (MM) affects both the innate and adaptive immune system. Molecules involved in the immune checkpoint pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of these molecules in predicting the kinetics of progression of MM. We retrospectively analysed polymorphisms of CTLA4 (rs231775 and rs733618), BTLA (rs9288953), CD28 (rs3116496), PD-1 (rs36084323 and rs11568821) and LAG-3 (rs870849) genes in 239 patients with newly diagnosed MM. Patients with a CTLA4 rs231775 AA/AG genotype showed a median progression-free survival (PFS) significantly lower than those with GG genotype (32.3 months versus 96.8 months respectively; p: 0.008). The 5-year PFS rate was 25% for patients with grouped AA and AG genotype vs 55.4% for patients with GG genotype. Multivariate analysis confirmed the CTLA4 rs231775 genotype as an independent risk factor for PFS (Hazard Ratio (HR): 2.05; 95% CI: 1.0-6.2; p: 0.047). Our results suggest that the CTLA4 genotype may identify patients with earlier progression of MM. This polymorphism could potentially be used as a prognostic biomarker.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Sixteen patients who had not achieved a complete response (CR), or a very good partial response (VGPR) pre-ASCT were enrolled in the study with the median age 55 years (range, 45-62). The median follow-up was 12 months (range, [7][8][9][10][11][12][13][14][15][16][17][18][19]. The study showed the encouraging results: at day+100 after ASCT ORR was 56% with CR in 31% pts with relative favorable therapy safety profile [18].…”

Section: Myeloma and Other Monoclonal Gammopathiesmentioning

confidence: 99%

“…Preclinical and clinical evidence suggests that the immune checkpoint programmed death-1 (PD-1) receptor/PD-1 ligand axis plays an important role in suppressing immune surveillance against MM, but monotherapy with anti-PD-1 antibody was not effective in patients with MM. The results of phase 1-2, single-arm study of nivolumab with ASCT in MM patients (NCT03292263) were presented by Pirogova O. et al [18]. Sixteen patients who had not achieved a complete response (CR), or a very good partial response (VGPR) pre-ASCT were enrolled in the study with the median age 55 years (range, 45-62).…”

Section: Myeloma and Other Monoclonal Gammopathiesmentioning

confidence: 99%

Highlights of the 24th European Hematology Association Congress, Amsterdam 2019

Fedorova¹,

Lepik²,

Popova³

et al. 2019

CTT

View full text Add to dashboard Cite

24 th Congress of European Hematology Association was held from 13 th to 16 th July in Amsterdam, Netherlands. Over 12000 specialists took part in the meeting and more than 360 oral and 1300 poster presentations were made, covering most of hematology fields. The main purpose of this article was to review the most important and relevant topics discussed during congress in such areas as hematopoietic stem cell transplantation, lymphomas, acute leukemia, multiple myeloma and other plasma cell disorders, myeloproliferative neoplasms and infectious complications in hematological patients. In this review, we briefly describe results of works which, in view of the authors, are of most clinical and scientific significance for hematopoietic stem cell transplantation. Moreover, the emerging topics and trends in different fields of hematology were discussed. Other interesting studies and presentations can be accessed through the EHA online-library.

show abstract